Authors: Curran, Monique P.; Robinson, Dean M.

Source: Drugs, Volume 69, Number 13, 10 September 2009 , pp. 1853-1878(26)

Publisher: Adis International

Abstract:

Abstract Aprepitant (Emend®) is a neurokinin-1 (NK₁) receptor antagonist that is able to alleviate the emetic effects of substance P. When combined with a standard regimen of a corticosteroid (dexamethasone) and a serotonin 5-HT₃ receptor antagonist (ondansetron), oral aprepitant (125 mg on day 1 then 80 mg once daily on days 2 and 3) was effective in the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with single or multiple cycles of highly emetogenic chemotherapy (HEC). This aprepitant regimen was also effective in the prevention of CINV in patients treated with single or multiple cycles of moderately emetogenic chemotherapy (MEC). A single oral dose of aprepitant 40 mg administered prior to patients undergoing abdominal surgery was also effective in the prevention of postoperative nausea and vomiting (PONV). Aprepitant was generally well tolerated. Aprepitant is a recommended option for the treatment of PONV, and when combined with a corticosteroid and 5-HT₃ receptor antagonist is a recommended regimen for the treatment of CINV.

Document Type: Research article

Affiliations: 1: 1Wolters Kluwer Health ∣ Adis, Auckland, New Zealand, an editorial office of Wolters Kluwer Health, Philadelphia, Pennsylvania, USA

Publication date: 2009-09-10

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology ,  Therapeutics & Alternative Medicine
• By this author: Curran, Monique P. ;  Robinson, Dean M.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers